BRPI0411901A - micropartìculas - Google Patents

micropartìculas

Info

Publication number
BRPI0411901A
BRPI0411901A BRPI0411901-0A BRPI0411901A BRPI0411901A BR PI0411901 A BRPI0411901 A BR PI0411901A BR PI0411901 A BRPI0411901 A BR PI0411901A BR PI0411901 A BRPI0411901 A BR PI0411901A
Authority
BR
Brazil
Prior art keywords
microparticles
oxycodone
plasticizer
extruding
lubricant
Prior art date
Application number
BRPI0411901-0A
Other languages
English (en)
Inventor
Malcolm Walden
Geoffrey Gerard Hayes
Hassan Mohammad
Harjit Tamber
Steve Whitelock
Vincenzo Martinelli
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33556051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411901(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0315137A external-priority patent/GB0315137D0/en
Priority claimed from GB0403102A external-priority patent/GB0403102D0/en
Priority claimed from GB0413454A external-priority patent/GB0413454D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BRPI0411901A publication Critical patent/BRPI0411901A/pt
Publication of BRPI0411901B1 publication Critical patent/BRPI0411901B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MICROPARTìCULAS". A presente invenção refere-se a múltiplas micropartículas de oxicodona, as quais podem ser produzidas mediante extrusão de uma mistura que, de forma adequada, contém: (a) oxicodona; (b) copolímero de metacrilato de amónio insolúvel em água; (c) plastificante; (d) lubrificante; e (e) agente modificador de permeabilidade à água.
BRPI0411901-0A 2003-06-27 2004-06-23 Multiparticulados extrudados de material fundido de liberação controlada, seu processo de preparação e composição farmacêutica na forma de dose unitária BRPI0411901B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0315137A GB0315137D0 (en) 2003-06-27 2003-06-27 Multiparticulates
GB0315137.0 2003-06-27
GB0403102.7 2004-02-12
GB0403102A GB0403102D0 (en) 2004-02-12 2004-02-12 Multiparticulates
GB0413454.0 2004-06-16
GB0413454A GB0413454D0 (en) 2004-06-16 2004-06-16 Multiparticulates
PCT/GB2004/002705 WO2005000310A1 (en) 2003-06-27 2004-06-23 Multiparticulates

Publications (2)

Publication Number Publication Date
BRPI0411901A true BRPI0411901A (pt) 2006-08-08
BRPI0411901B1 BRPI0411901B1 (pt) 2019-04-02

Family

ID=33556051

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411901-0A BRPI0411901B1 (pt) 2003-06-27 2004-06-23 Multiparticulados extrudados de material fundido de liberação controlada, seu processo de preparação e composição farmacêutica na forma de dose unitária

Country Status (25)

Country Link
EP (2) EP1644002B1 (pt)
JP (2) JP5348841B2 (pt)
KR (1) KR101116518B1 (pt)
AR (1) AR044935A1 (pt)
AT (1) ATE453394T1 (pt)
AU (1) AU2004251481B2 (pt)
BR (1) BRPI0411901B1 (pt)
CA (1) CA2530385C (pt)
CY (2) CY1109917T1 (pt)
DE (1) DE602004024888D1 (pt)
DK (2) DK1889621T3 (pt)
EA (1) EA013424B1 (pt)
ES (2) ES2490598T3 (pt)
HR (2) HRP20100127T1 (pt)
IL (1) IL172730A (pt)
MX (1) MXPA05013799A (pt)
MY (1) MY176831A (pt)
NO (1) NO20060443L (pt)
NZ (1) NZ544181A (pt)
PE (1) PE20050286A1 (pt)
PL (2) PL1644002T3 (pt)
PT (2) PT1644002E (pt)
SI (2) SI1889621T1 (pt)
TW (1) TWI357815B (pt)
WO (1) WO2005000310A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
CA2478515C (en) 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
SG169334A1 (en) * 2006-01-21 2011-03-30 Abbott Gmbh & Co Kg Dosage form and method for the delivery of drugs of abuse
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008109462A2 (en) * 2007-03-02 2008-09-12 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
RU2465916C2 (ru) 2007-10-19 2012-11-10 Оцука Фармасьютикал Ко., Лтд. Твердый фармацевтический препарат матричного типа
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
JP5539991B2 (ja) * 2008-09-18 2014-07-02 パーデュー、ファーマ、リミテッド、パートナーシップ ポリ（ε−カプロラクトン）を含む医薬剤形
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
CA2789377A1 (en) * 2010-02-11 2011-08-18 Harry Leider Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
HUT69680A (en) * 1990-08-09 1995-09-28 Endocon Inc Implant and apparatus for delivering multiple drug and process for production of theese
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
CA2182282C (en) * 1994-02-16 2006-04-18 Jacqueline E. Briskin Process for preparing fine particle pharmaceutical formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE69625822T2 (de) * 1995-05-01 2003-06-05 Sam Yang Co., Ltd. Implantierbare, bioresorbierbare membran und verfahren zu ihrer herstellung
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
AU3404997A (en) * 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
ATE526950T1 (de) * 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
AU776666B2 (en) * 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
CN1658836A (zh) * 2002-05-07 2005-08-24 控制传输系统公司 形成药物传递装置的方法
BRPI0406858A (pt) * 2003-01-24 2006-01-03 Control Delivery Sys Inc Liberação controlada de agentes altamente solúveis
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates

Also Published As

Publication number Publication date
NZ544181A (en) 2008-12-24
ES2337468T3 (es) 2010-04-26
JP5960089B2 (ja) 2016-08-02
IL172730A0 (en) 2006-04-10
EP1644002B1 (en) 2009-12-30
BRPI0411901B1 (pt) 2019-04-02
IL172730A (en) 2010-12-30
CA2530385A1 (en) 2005-01-06
DK1644002T3 (da) 2010-04-19
JP2013209387A (ja) 2013-10-10
HRP20140635T1 (hr) 2014-09-26
JP5348841B2 (ja) 2013-11-20
TW200510000A (en) 2005-03-16
EA013424B1 (ru) 2010-04-30
CY1109917T1 (el) 2014-09-10
CY1115415T1 (el) 2017-01-04
AR044935A1 (es) 2005-10-12
WO2005000310A1 (en) 2005-01-06
TWI357815B (en) 2012-02-11
AU2004251481B2 (en) 2010-01-28
EP1889621A1 (en) 2008-02-20
EA200600111A1 (ru) 2006-06-30
KR20060026892A (ko) 2006-03-24
PL1889621T3 (pl) 2014-10-31
DK1889621T3 (da) 2014-08-11
SI1644002T1 (sl) 2010-03-31
NO333779B1 (pt) 2013-09-16
PT1644002E (pt) 2010-03-03
SI1889621T1 (sl) 2014-09-30
MY176831A (en) 2020-08-24
PL1644002T3 (pl) 2010-05-31
EP1644002A1 (en) 2006-04-12
NO20060443L (no) 2006-01-27
ES2490598T3 (es) 2014-09-04
EP1889621B1 (en) 2014-05-21
AU2004251481A1 (en) 2005-01-06
DE602004024888D1 (de) 2010-02-11
PT1889621E (pt) 2014-08-27
KR101116518B1 (ko) 2012-03-13
CA2530385C (en) 2013-05-28
MXPA05013799A (es) 2006-03-13
JP2007520429A (ja) 2007-07-26
PE20050286A1 (es) 2005-06-13
ATE453394T1 (de) 2010-01-15
HRP20100127T1 (hr) 2010-04-30

Similar Documents

Publication Publication Date Title
CY1115415T1 (el) Πολυσωματιδια
BRPI0508758A (pt) processo para a preparação de cloridrato de oxicodona tendo menos que 25 ppm de 14 - hidroxicodeinona
BRPI0606145C1 (pt) formas farmacêuticas sólidas de cloridrato de oxicodona resistentes ao rompimento com liberação sustentada
IS2577B (is) Trópan afleiður sem CCR5 stillar
FR15C0005I2 (fr) Composes derives de benzothiazole, compositions et utilisations
BRPI0405450A (pt) Agente de revestimento
BR0316421A (pt) Composição farmacêutica compreendendo micropartìculas de octreotìdeo
ITMI20022716A1 (it) Innesto rapido con possibilita' di aggancio, rispettivamente
DE60217546D1 (de) Wässrige beschichtungszusammensetzungen die polyurethanacrylhybridpolymerdispersionen enthalten
MY141863A (en) Plastisols based on a methyl methacrylate copolymer
DE60332633D1 (de) Vierrädriges fahrzeug
JP2004114923A5 (pt)
EA200600066A1 (ru) Тамсулозинсодержащее ядро, покрытое поливинилпирролидоном или поливинилацетатом
EP1565458A4 (en) DIKATIONAL 2,5-DIARYLFURAN AZA ANALOGUE AS AGENT AGAINST PROTOZON
BRPI0501602A (pt) Componente composto
GT200400183A (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
ATE316104T1 (de) Kationische kern/schale-teilchen mit säure- quellbaren schalen
DE60231374D1 (de) Wässrige bimodale kunststoffdispersionen
ITRM20040436A1 (it) Complesso di infila-cavi con caratteristica di ritegno.
RU2000116332A (ru) Антгельминтное средство
Friedman Working out the kinks: Advancing the pornography debate
TH115315A (th) อนุภาครูปผสม
DE10391698D2 (de) Wasserverdünnbarer Vernetzer
ITPD20030307A1 (it) Slamatore con bloccaggio dell'amo
ES1055938Y (es) Guante de latex perfeccionado con fibra de estropajo.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: EURO-CELTIQUE S.A (LU)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.